EF Hutton analyst Constantine Davides maintained a Buy rating on Nemaura Medical (NMRD – Research Report) today and set a price target of $6.00. The company’s shares opened today at $0.93.
According to TipRanks, Davides is an analyst with an average return of -17.1% and a 36.00% success rate. Davides covers the Healthcare sector, focusing on stocks such as Acasti Pharma, Nemaura Medical, and Electromed.
Nemaura Medical has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, implying a 598.17% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.58 and a one-year low of $0.87. Currently, Nemaura Medical has an average volume of 158.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Through its subsidiaries, it manufactures and commercializes continuous glucose monitoring system, named sugarBEAT. The sugarBEAT is consist of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in Loughborough, the United Kingdom.
Read More on NMRD:
- Nemaura Medical price target lowered to $7 from $8 at H.C. Wainwright
- Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
- Nemaura Medical reports Q3 EPS (7c), consensus (18c)
- Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
- Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
